Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,983 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OTLKW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.01 +200.00%
on 02/16/22
0.10 -68.75%
on 02/11/22
-0.02 (-40.00%)
since 01/14/22
3-Month
0.01 +200.00%
on 02/16/22
0.30 -90.00%
on 12/03/21
-0.13 (-81.18%)
since 11/16/21
52-Week
0.01 +200.00%
on 02/16/22
1.44 -97.91%
on 02/17/21
-1.32 (-97.79%)
since 02/16/21

Most Recent Stories

More News
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones

Planned re-submission of ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD

ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update

ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics to Participate in Retina World Congress 2022

ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight

Live moderated video webcast on Wednesday, May 11th at 1:00 PM ET...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics

SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical...

OTLKW : 0.03 (-1.96%)
OTLK : 8.50 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.07
2nd Resistance Point 0.05
1st Resistance Point 0.04
Last Price 0.03
1st Support Level 0.02
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 1.44
Fibonacci 61.8% 0.89
Fibonacci 50% 0.72
Fibonacci 38.2% 0.55
Last Price 0.03
52-Week Low 0.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar